These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 38508132)
1. Neoadjuvant treatment for pancreatic cancer: Controversies and advances. Dias E Silva D; Chung V Cancer Treat Res Commun; 2024; 39():100804. PubMed ID: 38508132 [TBL] [Abstract][Full Text] [Related]
2. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842 [TBL] [Abstract][Full Text] [Related]
3. [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer]. Bai XL; Li X; Liang TB Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):486-489. PubMed ID: 32610415 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis. Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602 [TBL] [Abstract][Full Text] [Related]
5. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. Goff SL; Chabot JA Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848 [TBL] [Abstract][Full Text] [Related]
6. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278 [TBL] [Abstract][Full Text] [Related]
7. The role of neoadjuvant therapy in pancreatic cancer: a review. Russo S; Ammori J; Eads J; Dorth J Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant strategies for pancreatic cancer. Polistina F; Di Natale G; Bonciarelli G; Ambrosino G; Frego M World J Gastroenterol; 2014 Jul; 20(28):9374-83. PubMed ID: 25071332 [TBL] [Abstract][Full Text] [Related]
11. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009 [TBL] [Abstract][Full Text] [Related]
12. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Katz MH; Landry J; Kindler HL Am Soc Clin Oncol Educ Book; 2014; ():e157-64. PubMed ID: 24857097 [TBL] [Abstract][Full Text] [Related]
13. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238 [TBL] [Abstract][Full Text] [Related]
14. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts. Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495 [TBL] [Abstract][Full Text] [Related]
16. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Blair AB; Sorber R; Rozich NS; Burkhart RA Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483 [TBL] [Abstract][Full Text] [Related]
17. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409 [TBL] [Abstract][Full Text] [Related]
18. Advances and challenges of neoadjuvant therapy in pancreatic cancer. Yu Y; Zheng P; Chen Y; Wang B; Paul ME; Tao P; Wang D; Li H; Gu B; Gao L; Wang D; Chen H Asia Pac J Clin Oncol; 2021 Dec; 17(6):425-434. PubMed ID: 33164329 [TBL] [Abstract][Full Text] [Related]
19. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer. Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309 [TBL] [Abstract][Full Text] [Related]
20. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy]. Zhang TP; Liu YZ; Cao Z Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]